Richa Patel, MD
Endocrinology, Diabetes & Metabolism · Cincinnati, OHNPI 1689930091
Payments from drug & device makers
Across 165 payments — averaging $22.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Dexcom, Inc.$719
- Novo Nordisk$537
- Lilly USA, LLC$378
- AstraZeneca$335
- Sanofi-aventis U.S. LLC$165
- BETA Bionics, Inc.$163
- plus $1K from 24 others
What the payments were for
- Food & beverage$3,54896%
- Education$782%
- Gifts$592%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Dexcom, Inc. | 17 | $719 |
| Novo Nordisk | 32 | $537 |
| Lilly USA, LLC | 29 | $378 |
| AstraZeneca | 11 | $335 |
| Sanofi-aventis U.S. LLC | 11 | $165 |
| BETA Bionics, Inc. | 2 | $163 |
| Boston Scientific | 1 | $145 |
| Xeris Pharmaceuticals, Inc. | 2 | $134 |
| Valeritas, Inc. | 10 | $127 |
| Amgen | 3 | $126 |
| Insulet Corporation | 9 | $124 |
| AbbVie | 6 | $90 |
| Tandem Diabetes Care, Inc. | 6 | $89 |
| Medtronic | 1 | $81 |
| Mannkind Corporation | 1 | $59 |
| Ascensia Diabetes Care US Inc. | 1 | $50 |
| Abbott | 2 | $46 |
| Merck | 3 | $45 |
| Shire North American Group Inc | 2 | $32 |
| Lifescan, Inc. | 2 | $31 |
| Amarin Pharma, Inc. | 2 | $31 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $30 |
| Amneal Pharmaceuticals LLC | 1 | $27 |
| Johnson & Johnson | 2 | $24 |
| Senseonics, Incorporated | 2 | $24 |
| Evoke Pharma, Inc. | 1 | $19 |
| Corcept Therapeutics | 1 | $17 |
| Pfizer | 1 | $14 |
| Boehringer Ingelheim | 1 | $14 |
| Regeneron Healthcare Solutions, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- iLet Bionic Pancreas$417
- DEXCOM G6 TRANSMITTER$247
- FARXIGA$214
- WaveWriter Alpha Prime 16$145
- MOUNJARO$121
- GVOKE HYPOPEN$118
How this compares
$3,686 in reported general payments places this provider in the 65th percentile of 312 endocrinology, diabetes & metabolism providers in Ohio.
See all endocrinology, diabetes & metabolism providers in Ohio →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 199 | $220,207 |
| TrulicityDulaglutide | 131 | $159,989 |
| JardianceEmpagliflozin | 113 | $146,367 |
| MounjaroTirzepatide | 79 | $96,804 |
| Humalog Kwikpen U-200Insulin Lispro | 16 | $52,504 |
| JanuviaSitagliptin Phosphate | 34 | $48,699 |
| Tresiba Flextouch U-200Insulin Degludec | 37 | $43,944 |
| FarxigaDapagliflozin Propanediol | 34 | $40,309 |
| Tresiba Flextouch U-100Insulin Degludec | 42 | $30,280 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 30 | $23,655 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 34 | $22,630 |
| Humalog Kwikpen U-100Insulin Lispro | 46 | $21,543 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 11 | $20,080 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 134 | $18,701 |
| Novolog FlexpenInsulin Aspart | 46 | $16,226 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro, Humalog, Insulin Lispro | $378 | $263,807242 claims |
| Novo NordiskOzempic, Novolog | $537 | $225,448212 claims |
| Boehringer IngelheimJardiance | $14 | $146,367113 claims |
| MerckJanuvia | $45 | $48,69934 claims |
| AstraZenecaFarxiga | $335 | $40,30934 claims |
| AbbVieSynthroid | $90 | $5,58078 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $27 | $4,696372 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 312 endocrinology, diabetes & metabolism providers in Ohio.
Other endocrinology, diabetes & metabolism in Cincinnati
- Nelson WattsCincinnati$348K
- Shawn PeavieCincinnati$201K
- Amanda DenneyCincinnati$183K
- Robert CohenCincinnati$136K
- Shailendra PatelCincinnati$68K
- Toby BriskinBedford$9.8M
- Charles SmithCanton$5.3M
- Kevin PantaloneCleveland$4M
- Elena ChristofidesColumbus$3.5M
- Arvind KrishnaCanton$3.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.